Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.

Cancer gene therapy - 1 Apr 2024

Li Gan-Xun, Chang Rui-Zhi, Liu Tong-Tong, Jin Guan-Nan, Lu Kan, Yong Tu-Ying, Li Zifu, Liu Ji-Hong, Zhang Bixiang, Zhang Wan-Guang, Ding Ze-Yang

Abstract excerpt

Glutamate-NMDAR receptors (GRINs) have been reported to influence cancer immunogenicity; however, the relationship between GRIN alterations and the response to immune checkpoint inhibitors (ICIs) has not been determined. This study combined clinical characteristics and mutational profiles from multiple cohorts to form a discovery cohort (n = 901). The aim of this study was to investigate the correlation between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 38267623
DOI: 10.1038/s41417-024-00730-6

Genes

GRIN2A

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.PMID 38267623Read ↗

Genetic and Functional Analysis of GRIN2A in Tumor Samples.Semantic proximity Read ↗

GRIN3A defines an immunosuppressive niche in advanced prostate cancerSemantic proximity Read ↗

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy.Semantic proximity Read ↗

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironmentsSemantic proximity Read ↗

Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple CancersSemantic proximity Read ↗

Evaluation of NTRK3 mutation and a mutation-based gene set as biomarkers for immunotherapy outcomes in multiple cancersSemantic proximity Read ↗

Exome sequencing identifies GRIN2A as frequently mutated in melanoma.Semantic proximity Read ↗

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.Semantic proximity Read ↗

Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.Semantic proximity Read ↗

Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity Read ↗

Unveiling Key Immune Genes and Drug Candidates for Krabbe Disease in Human iPSCs-derived NSCsSemantic proximity Read ↗

Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.